Anti-diabetic actions of carbon monoxide-releasing molecule (CORM)-A1: Immunomodulation and regeneration of islet beta cells
- 1 May 2015
- journal article
- Published by Elsevier in Immunology Letters
- Vol. 165 (1) , 39-46
Abstract
No abstract availableKeywords
Funding Information
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja (173013)
- European Foundation for the Study of Diabetes
This publication has 41 references indexed in Scilit:
- Carbon Monoxide Abrogates Ischemic Insult to Neuronal Cells via the Soluble Guanylate Cyclase-cGMP PathwayPLOS ONE, 2013
- Foxp3+Regulatory T Cells in Mouse Models of Type 1 DiabetesJournal of Diabetes Research, 2013
- Carbon monoxide‐treated dendritic cells decrease β1‐integrin induction on CD8+ T cells and protect from type 1 diabetesEuropean Journal of Immunology, 2012
- Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1Clinical and Experimental Immunology, 2011
- β-Cell Growth and Regeneration: Replication Is Only Part of the StoryDiabetes, 2010
- IL-2-deprivation and TGF-β are two non-redundant suppressor mechanisms of CD4+CD25+ regulatory T cell which jointly restrain CD4+CD25− cell activationImmunology Letters, 2010
- The RCK1 high-affinity Ca 2+ sensor confers carbon monoxide sensitivity to Slo1 BK channelsProceedings of the National Academy of Sciences, 2008
- Carbon monoxide-releasing molecules (CO-RMs): vasodilatory, anti-ischaemic and anti-inflammatory activitiesBiochemical Society Transactions, 2007
- Critical role of heme oxygenase-1 in Foxp3-mediated immune suppressionBiochemical and Biophysical Research Communications, 2005
- Expression of functional IL-2 receptors on mature splenic dendritic cellsEuropean Journal of Immunology, 2000